Triple-negative breast cancer is a heterogeneous disease and specific therapies have not
been available for a long time. Therefore, conventional chemotherapy is still considered the …

Background The role of platinum-based neoadjuvant chemotherapy in triple-negative breast
cancer (TNBC) patients is highly controversial and it is not endorsed by current guidelines …

Triple negative breast cancer (TNBC) constitutes the most aggressive molecular subtype
among breast tumors. Despite progress on the underlying tumor biology, clinical outcomes …

Triple-negative breast cancer (TNBC) is a breast cancer subtype renowned for its capacity to
affect younger women, metastasise early despite optimal adjuvant treatment and carry a …

Purpose One third of patients with triple-negative breast cancer (TNBC) achieve pathologic
complete response (pCR) with standard neoadjuvant chemotherapy (NACT). CALGB 40603 …

Triple-negative breast cancers (TNBCs) are defined by the absence of estrogen and
progesterone receptors and the absence of HER2 overexpression. These cancers represent …

Background Preclinical data suggest that triple-negative breast cancers are sensitive to
interstrand crosslinking agents, and that synergy may exist for the combination of a taxane …

Background Treatment options for women presenting with triple negative breast cancer
(TNBC) are limited due to the lack of a therapeutic target and as a result, are managed with …

Background The antitumor efficacy of PARP inhibitors (PARPi) for breast cancer patients
harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi …

Author links open overlay panel F. Cardoso a, A. Costa bc, L. Norton d, E. Senkus e, M.
Aapro f, F. André g, CH Barrios h, J. Bergh i, L. Biganzoli j, KL Blackwell k, MJ Cardoso l, T …